Toward Autonomous Antibiotic Discovery.

@inproceedings{delaFuenteNunez2019TowardAA,
  title={Toward Autonomous Antibiotic Discovery.},
  author={Cesar de la Fuente-Nunez},
  year={2019}
}
ABSTRACT Machines hold the potential to replace humans in many societal endeavors, and drug discovery is no exception. Antibiotic innovation has been stalled for decades, which has coincided with an alarming increase in multidrug-resistant bacteria. Since the beginning of the antibiotic era, the natural world has been our greatest innovator, giving rise to nearly all antibiotics available today. As mere observers of the vast molecular diversity produced by Earth’s organisms, we have perfected… 

Accelerating antibiotic discovery through artificial intelligence

TLDR
This review describes AI-facilitated advances in the discovery of both small molecule antibiotics and antimicrobial peptides and analyzes uptake of open science best practices in AI-driven antibiotic discovery and argues for openness and reproducibility as a means of accelerating preclinical research.

Reprogramming biological peptides to combat infectious diseases.

TLDR
Several new strategies that have been developed to counter pathogenic microorganisms by designing and constructing antimicrobial peptides (AMPs) are outlined.

Reprogramming biological peptides to combat infectious diseases.

TLDR
Several new strategies that have been developed to counter pathogenic microorganisms by designing and constructing antimicrobial peptides (AMPs) are outlined.

Towards the sustainable discovery and development of new antibiotics

TLDR
This consortium presents a strategic blueprint to substantially improve the ability to discover and develop new antibiotics, and proposes both short-term and long-term solutions to this challenge.

Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy

TLDR
What is believed to be the key considerations for AST of AMP are described and it is hoped that this information can better guide the preclinical development of AMp toward becoming a new generation of urgently needed antimicrobials.

References

SHOWING 1-10 OF 15 REFERENCES

What can machine learning do for antimicrobial peptides, and what can antimicrobial peptides do for machine learning?

TLDR
It is shown that machine learning on AMPs can be used to identify essential physico-chemical determinants of AMP functionality, and identify and design peptide sequences to generate membrane curvature.

Structure-function-guided exploration of the antimicrobial peptide polybia-CP identifies activity determinants and generates synthetic therapeutic candidates

TLDR
It is demonstrated that, by tuning these physicochemical parameters, it is possible to design nontoxic synthetic peptides with enhanced sub-micromolar antimicrobial potency in vitro and anti-infective activity in vivo and to generate peptide antibiotics.

In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design

TLDR
A computational algorithm is developed that starts with peptides naturally occurring in plants and optimizes this starting material to yield new variants which are highly distinct from the parent peptide, which could be used to design effective peptide antibiotics.

APD3: the antimicrobial peptide database as a tool for research and education

TLDR
Newly annotated are AMPs with antibiofilm, antimalarial, anti-protist, insecticidal, spermicidal, chemotactic, wound healing, antioxidant and protease inhibiting properties and various database applications in research and education are summarized.

Sparse Neural Network Models of Antimicrobial Peptide‐Activity Relationships

TLDR
The results of this study underscore the applicability of neural networks for guiding the computer‐assisted design of new peptides with desired properties when predicting antimicrobial peptides from the amino acid sequence.